PCPE-2 Peptides Inhibit BMP-1 Proteases for Fibrosis Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack specific and efficient inhibitors for bone morphogenetic protein-1 (BMP-1) and mammalian tolloid-like 1 (mTLL-1) proteases, which are crucial for extracellular matrix assembly and growth factor activation, leading to challenges in treating fibrosis and cancer, as existing inhibitors are either non-specific or pose immunogenicity risks.
Innovation Solution
Development of novel peptides derived from the CUB1 domain of procollagen C-proteinase enhancer-2 (PCPE-2) that specifically inhibit BMP-1/tolloid-like proteases by binding and inhibiting their activity, offering a targeted approach to modulate their function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing inhibitors are used to block BTP activity, then fibrosis and cancer progression can be inhibited, but the inhibitors are either non-specific or pose immunogenicity risks
Solution Approach 1:
The invention extracts and utilizes the natural inhibitory domain (CUB1 domain) from the endogenous PCPE-2 protein to create peptide inhibitors. This approach takes out the specific inhibitory function already present in the mammalian system, ensuring both specificity and lack of immunogenicity since the peptides are derived from human proteins
Solution Approach 2:
The invention employs self-service by using endogenous mammalian proteins (PCPE-2 and its CUB1 domain) as the basis for inhibition. The body's own protein structures are used to regulate BTP activity, eliminating the need for foreign inhibitors that would trigger immune responses
2Reliability
If BTP activity is inhibited to treat fibrosis, then extracellular matrix deposition is reduced, but existing inhibitors lack specificity for BTPs
Solution Approach 1:
The invention applies local quality by designing peptides with specific sequences (such as SEQ ID NO:1 and its variants) that are tailored to bind specifically to BTP active sites. The CUB1 domain structure provides localized specific interaction with BTPs while maintaining the ability to treat multiple conditions involving BTP dysregulation
3Productivity
If BTP activity is enhanced to promote tissue repair, then wound healing is improved, but uncontrolled BTP activity contributes to fibrosis and cancer
Solution Approach 1:
The invention applies dynamics by providing a reversible and regulatable inhibition mechanism. The peptide inhibitors can dynamically control BTP activity levels, allowing enhancement when needed for tissue repair while preventing uncontrolled activity that leads to fibrosis and cancer. The inhibition can be modulated by adjusting peptide concentration and timing of administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PCPE-2-derived peptides effectively inhibit BMP-1 and mTLL-1 proteases, potentially treating fibrotic disorders, cancers, and metabolic diseases by regulating their activity, providing a specific and potent therapeutic option without the immunogenicity concerns of existing inhibitors.
Implementation Method 1
BMP-1 and mTLL-1 are two essential extracellular metalloproteases for mammalian life... They proteolytically remove the C-terminal propeptide of fibrillar procollagens... The PCPE-2-derived peptides effectively inhibit BMP-1 and mTLL-1 proteases
Data Source
Figure 1~2
Figure 3~4
Figure 5A~5C
AI summary
The present invention relates to peptide comprising the amino acid sequence SEQ ID NO :1, provided that said peptide does not consist in SEQ ID NO: 2, or SEQ ID NO: 3 or any variant thereof having at least 36% identity with SEQ ID NO: 1 or SEQ ID NO: 3, provided that the underlined cysteines (C) in SEQ ID NO: 1 are conserved, and that the variant does not contain another cysteine, and that said variant retains the ability to bind and/or inhibit a BMP-1/tolloid-like protease or BTP. The use of the peptide in therapy is also disclosed.